Comparative Pharmacology
Head-to-head clinical analysis: NAMENDA versus NAMENDA XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAMENDA versus NAMENDA XR.
NAMENDA vs NAMENDA XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Memantine is an uncompetitive, low-affinity N-methyl-D-aspartate (NMDA) receptor antagonist. It binds to the NMDA receptor at the magnesium binding site and blocks excessive glutamate-mediated excitotoxicity while allowing normal physiological neurotransmission.
Memantine is an uncompetitive, moderate-affinity N-methyl-D-aspartate (NMDA) receptor antagonist that binds preferentially to NMDA receptor-operated cation channels. It blocks the effects of excess glutamate, which can lead to neuronal excitotoxicity, without interfering with normal synaptic transmission.
Initial: 5 mg orally once daily; increase by 5 mg/day every 4 weeks to target dose of 10 mg twice daily (total 20 mg/day).
28 mg orally once daily, after titration; initial dose 7 mg once daily, increase by 7 mg every 7 days to target dose.
None Documented
None Documented
Thiazide-like: chlorthalidone 40-60 h (prolonged due to RBC binding); thiazide: hydrochlorothiazide 6-15 h (clinical effect persists due to prolonged renal action).
Terminal elimination half-life is 60-80 hours (mean 70 h) in young adults, prolonged to 80-120 h in elderly due to reduced renal function; steady-state is achieved in 3-4 weeks.
Primarily renal (hydrochlorothiazide: 70% unchanged; metolazone: 80% unchanged; chlorthalidone: 50% unchanged). Biliary/fecal elimination minimal (<10%).
Renal elimination of unchanged drug (57-82%) and metabolites, with ~20% fecal excretion. Total renal clearance is predominantly via tubular secretion.
Category C
Category C
NMDA Antagonist
NMDA Antagonist